JP2021050218A5 - - Google Patents

Download PDF

Info

Publication number
JP2021050218A5
JP2021050218A5 JP2020200158A JP2020200158A JP2021050218A5 JP 2021050218 A5 JP2021050218 A5 JP 2021050218A5 JP 2020200158 A JP2020200158 A JP 2020200158A JP 2020200158 A JP2020200158 A JP 2020200158A JP 2021050218 A5 JP2021050218 A5 JP 2021050218A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tyrosine kinase
kinase inhibitor
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020200158A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840031B2 (ja
JP2021050218A (ja
Filing date
Publication date
Priority claimed from JP2017539224A external-priority patent/JP6854766B2/ja
Application filed filed Critical
Publication of JP2021050218A publication Critical patent/JP2021050218A/ja
Publication of JP2021050218A5 publication Critical patent/JP2021050218A5/ja
Priority to JP2023015070A priority Critical patent/JP2023052878A/ja
Priority to JP2025005945A priority patent/JP2025061369A/ja
Application granted granted Critical
Publication of JP7840031B2 publication Critical patent/JP7840031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020200158A 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法 Active JP7840031B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023015070A JP2023052878A (ja) 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2025005945A JP2025061369A (ja) 2015-01-26 2025-01-16 チロシンキナーゼ阻害剤を用いる組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US62/107,553 2015-01-26
US201562250052P 2015-11-03 2015-11-03
US62/250,052 2015-11-03
JP2017539224A JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017539224A Division JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015070A Division JP2023052878A (ja) 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法

Publications (3)

Publication Number Publication Date
JP2021050218A JP2021050218A (ja) 2021-04-01
JP2021050218A5 true JP2021050218A5 (https=) 2021-07-26
JP7840031B2 JP7840031B2 (ja) 2026-04-03

Family

ID=56544226

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017539224A Active JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2020200158A Active JP7840031B2 (ja) 2015-01-26 2020-12-02 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2023015070A Pending JP2023052878A (ja) 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2025005945A Pending JP2025061369A (ja) 2015-01-26 2025-01-16 チロシンキナーゼ阻害剤を用いる組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017539224A Active JP6854766B2 (ja) 2015-01-26 2016-01-26 チロシンキナーゼ阻害剤を用いる組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023015070A Pending JP2023052878A (ja) 2015-01-26 2023-02-03 チロシンキナーゼ阻害剤を用いる組成物および方法
JP2025005945A Pending JP2025061369A (ja) 2015-01-26 2025-01-16 チロシンキナーゼ阻害剤を用いる組成物および方法

Country Status (6)

Country Link
US (4) US10471059B2 (https=)
EP (2) EP4653015A3 (https=)
JP (4) JP6854766B2 (https=)
CN (2) CN107530298B (https=)
MX (2) MX2017009643A (https=)
WO (1) WO2016123086A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2019246121A1 (en) * 2018-06-18 2019-12-26 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
WO2020117962A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP3930715B1 (en) * 2019-02-27 2024-05-08 Astrazeneca AB Saracatinib for use in the treatment of idiopathic pulmonary fibrosis
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20240075031A1 (en) * 2020-12-07 2024-03-07 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
WO2023175136A1 (en) * 2022-03-18 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025031474A1 (en) * 2023-08-10 2025-02-13 Insilico Medicine Ip Limited Method and medicament for treating endometriosis
WO2025111752A1 (zh) * 2023-11-27 2025-06-05 中山大学 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
WO2025170008A1 (ja) * 2024-02-07 2025-08-14 国立大学法人京都大学 成熟心筋細胞の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
WO2001034201A2 (en) 1999-11-12 2001-05-17 Advanced Research And Technology Institute, Inc. Methods for inhibiting neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101056539B (zh) * 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007047919A2 (en) * 2005-10-20 2007-04-26 University Of South Florida Treatment of restenosis and stenosis with dasatinib
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
WO2008054792A2 (en) 2006-10-31 2008-05-08 University Of Toledo Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
EP2988738A4 (en) * 2013-01-10 2016-11-09 Pulmokine Inc THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
US9783504B2 (en) * 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2021050218A5 (https=)
JP2018504416A5 (https=)
Lim et al. Is targeting autophagy mechanism in cancer a good approach? The possible double-edge sword effect
Urner-Bloch et al. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects
Sebti et al. Farnesyltransferase inhibitors
Yatham et al. Agomelatine or placebo as adjunctive therapy to a moodstabiliser in bipolar I depression: Randomised double-blindplacebo-controlled trial
Navarro-López et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction
Radcliffe et al. Challenging the" Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution
Westman et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial
ES2972329T3 (es) Supresor de neovascularización coroidea o supresor de formación de drusas y método para evaluar o detectar las mismas
Fan et al. Pharmacological inhibition of focal adhesion kinase attenuates cardiac fibrosis in mice cardiac fibroblast and post-myocardial-infarction models
JP2020508971A (ja) 老化細胞が介在する疾患を治療するためのペプチド系プロテアソーム阻害物質、およびがんを治療するためのペプチド系プロテアソーム阻害物質
US20220017485A1 (en) Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
Sabri et al. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma
AU2011290857A1 (en) Novel combination therapy for the treatment of cancer
MX2011010631A (es) Metodos y composiciones de inhibidores de quinasa pi-3 para tratar fibrosis.
US20160120871A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
JP2007537184A (ja) 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
Yener et al. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay
US11672812B2 (en) Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer
US20220331310A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
KR102501677B1 (ko) 프리마퀸 디포스페이트와 그 타겟으로 usp1의 혈관누수차단 효과
BR112020011056A2 (pt) métodos para o tratamento da doença de gaucher
JP6328856B2 (ja) 収縮力低下随伴性排尿筋過活動改善剤
Samantas et al. Combination chemotherapy with low doses of weekly carboplatin and oral etoposide in poor risk small cell lung cancer